Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Phase 2 Recruiting
44 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase 2/3 Recruiting
613 enrolled
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Phase 1 Recruiting
11 enrolled
AHEAD-MERIT
Phase 2/3 Recruiting
350 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Phase 3 Recruiting
158 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
40 enrolled
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Phase 1 Recruiting
22 enrolled
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Phase 2 Recruiting
120 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
92 enrolled
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Phase 1/2 Recruiting
40 enrolled
OrigAMI-4
Phase 1/2 Recruiting
287 enrolled
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Phase 2 Recruiting
30 enrolled
LUMIRAY
Phase 1 Recruiting
30 enrolled
OrigAMI-5
Phase 3 Recruiting
500 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
FIERCE-HN
Phase 3 Recruiting
410 enrolled
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2 Recruiting
100 enrolled
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
40 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
STEALTH-001
Phase 1 Recruiting
60 enrolled
HOPE
Phase 3 Recruiting
228 enrolled
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
GALENOS 2
Phase NA Recruiting
52 enrolled
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Phase NA Recruiting
48 enrolled
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
1,000 enrolled
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
500 enrolled
GALENOS 1
Recruiting
110 enrolled
BIOMATCH
Recruiting
300 enrolled
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Phase 2/3 Recruiting
686 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
DART-HN
Phase NA Recruiting
40 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Phase 3 Recruiting
500 enrolled
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 Recruiting
150 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled